Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.60 |
| ▸ | HTR2A | P28223 | 2/20 | 0.54 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20425554 | 1.00 | TAAR1 (0.60) | TAAR1HTR2AALOX5MAOAPYCR1 | |
| SCHEMBL12378777 | 1.00 | TAAR1 (0.60) | TAAR1HTR2AALOX5MAOAPYCR1 | |
| Hydrochloric Acid SCHEMBL5877710 | 0.98 | TAAR1 (0.58) | TAAR1HTR2AALOX5MAOAPYCR1 | |
| Hydrochloric Acid SCHEMBL5877704 | 0.98 | TAAR1 (0.58) | TAAR1HTR2AALOX5MAOAPYCR1 | |
| Hydrochloric Acid SCHEMBL5877780 | 0.98 | TAAR1 (0.58) | TAAR1HTR2AALOX5MAOAPYCR1 | |
| SCHEMBL3006604 | 0.87 | TAAR1 (0.75) | TAAR1HTR2AALDH1A1ALOX15 | |
| Hydrochloric Acid SCHEMBL6564727 | 0.85 | TAAR1 (0.71) | TAAR1HTR2AALOX15 | |
| SCHEMBL14966455 | 0.82 | HTR2A (0.45) | TAAR1HTR2AALOX5MAOAPYCR1 | |
| SCHEMBL10456468 | 0.78 | PYCR1 (0.41) | HTR2AALOX5MAOAPYCR1CYP2A6 | |
| SCHEMBL14221288 | 0.78 | ALDH1A1 (0.44) | HTR2AALOX5PYCR1CYP2A6ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024097228-A1 | COMPOUNDS TARGETING CDK11 AND METHODS OF USING THE SAME | MELIORA THERAPEUTICS, INC. (US) | 2024-05-10 | — | — | WO | disclosed |
| WO-2024010529-A1 | PRODUCTION OF ENANTIOPURE ALCOHOLS, AMINES AND ACIDS FROM RACEMIC EPOXIDES BY CASCADE BIOTRANSFORMATION INVOLVING EPOXIDE ISOMERIZATION AND DYNAMIC KINETIC RESOLUTION | NATIONAL UNIVERSITY OF SINGAPORE (SG) | 2024-01-11 | — | — | WO | disclosed |
| US-20220048884-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. | 2022-02-17 | — | — | US | disclosed |
| CN-105189497-B | N- (2- cyano heterocycle) Pyrazolopyridine ketone as JANUS kinase inhibitor | 默沙东公司 | 2019-05-03 | — | — | CN | disclosed |
| CN-108864076-A | glucosylceramide synthase inhibitors | 建新公司 | 2018-11-23 | — | — | CN | disclosed |
| CN-108368083-A | heteroaryl compounds and their use as therapeutic agents | 东亚首希控股股份有限公司 | 2018-08-03 | — | — | CN | disclosed |
| WO-2018140876-A1 | NRF2 ACTIVATOR | BIOGEN MA INC. (US) | 2018-08-02 | — | — | WO | disclosed |
| CN-105073745-B | glucosylceramide synthase inhibitors | 建新公司 | 2018-06-29 | — | — | CN | disclosed |
| CN-107872976-A | Method for treatment albumen matter disease | 建新公司 | 2018-04-03 | — | — | CN | disclosed |
| CN-107080747-A | Glucosylceramide synthase inhibitor | 建新公司 | 2017-08-22 | — | — | CN | disclosed |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | ASTRAZENECA AB (SE) | 2005-11-03 | — | — | US | disclosed |
| CN-1688550-A | 2, 5-dioxoimidazolidin-4-yl acetamides and analogs as metalloproteinase MMP12 inhibitors | ASTRAZENECA AB (SE) | 2005-10-26 | — | — | CN | disclosed |
| EP-1542977-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | AstraZeneca AB (SE) | 2005-06-22 | — | — | EP | disclosed |
| EP-1421074-A1 | NOVEL COMPOUNDS | AstraZeneca AB (SE) | 2004-05-26 | — | — | EP | disclosed |
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | ARNOLD MACKLIN BRIAN (US) | 2004-05-20 | — | — | US | disclosed |
| WO-2004020415-A1 | 2,5-DIOXOIMIDAZOLIDIN-4-YL ACETAMIDES AND ANALOGUES AS INHIBITORS OF METALLOPROTEINASE MMP12. | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
| US-6617351-B1 | Amide, carbamate, and urea derivatives | ELI LILLY AND COMPANY | 2003-09-09 | — | — | US | disclosed |
| WO-2003010158-A1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2003-02-06 | — | — | WO | disclosed |
| WO-2000006156-A1 | AMIDE, CARBAMATE, AND UREA DERIVATIVES | ELI LILLY AND COMPANY (US) | 2000-02-10 | — | — | WO | disclosed |
| EP-0976744-A1 | Amide, carbamate, and urea derivatives having glutamate receptor function potentiating activity | ELI LILLY AND COMPANY (US) | 2000-02-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220048884-A1 | NRF2 ACTIVATOR | NFE2L2, KEAP1, NQO1 | TAAR1 3550/4885HTR2A 2000/4885ALOX5 629/4885 |
| US-20040097499-A1 | Amide, carbamate, and urea derivatives | GRIN2A, GLUL, GRIK5 | TAAR1 135/4885HTR2A 301/4885ALOX5 3689/4885 |
| US-20050245586-A1 | 2,5-Dioxoimidazolidin-4-yl acetamides and analogues as inhibitors of metalloproteinase mmp12 | MMP12, PDE12, MMP13 | TAAR1 3540/4885HTR2A 2729/4885ALOX5 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.